300 related articles for article (PubMed ID: 35188766)
1. Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation.
Wang T; Cai S; Cheng Y; Zhang W; Wang M; Sun H; Guo B; Li Z; Xiao Y; Jiang S
J Med Chem; 2022 Mar; 65(5):3879-3893. PubMed ID: 35188766
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Novel PD-L1 Inhibitors That Induce the Dimerization, Internalization, and Degradation of PD-L1 Based on the Fragment Coupling Strategy.
Wang K; Zhang X; Cheng Y; Qi Z; Ye K; Zhang K; Jiang S; Liu Y; Xiao Y; Wang T
J Med Chem; 2023 Dec; 66(24):16807-16827. PubMed ID: 38109261
[TBL] [Abstract][Full Text] [Related]
3. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway.
Wu Q; Jiang L; Li SC; He QJ; Yang B; Cao J
Acta Pharmacol Sin; 2021 Jan; 42(1):1-9. PubMed ID: 32152439
[TBL] [Abstract][Full Text] [Related]
4. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
5. Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.
Wang T; Cai S; Wang M; Zhang W; Zhang K; Chen D; Li Z; Jiang S
J Med Chem; 2021 Jun; 64(11):7390-7403. PubMed ID: 34056906
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy.
Zhang H; Xia Y; Yu C; Du H; Liu J; Li H; Huang S; Zhu Q; Xu Y; Zou Y
Molecules; 2021 Jun; 26(11):. PubMed ID: 34199417
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Blockade Mediated by a Small-Molecule Nanoinhibitor Targeting the PD-1/PD-L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer.
Zhang R; Zhu Z; Lv H; Li F; Sun S; Li J; Lee CS
Small; 2019 Dec; 15(49):e1903881. PubMed ID: 31702880
[TBL] [Abstract][Full Text] [Related]
8. Advances of biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction in cancer immunotherapy.
Chen R; Yuan D; Ma J
Future Med Chem; 2022 Jan; 14(2):97-113. PubMed ID: 34870447
[TBL] [Abstract][Full Text] [Related]
9. Reducing PD-L1 Expression by Degraders and Downregulators as a Novel Strategy to Target the PD-1/PD-L1 Pathway.
Wang Z; Yuan L; Liao X; Guo X; Chen J
J Med Chem; 2024 Apr; 67(8):6027-6043. PubMed ID: 38598179
[TBL] [Abstract][Full Text] [Related]
10. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
11. Benzosceptrin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3.
Wang Q; Wang J; Yu D; Zhang Q; Hu H; Xu M; Zhang H; Tian S; Zheng G; Lu D; Hu J; Guo M; Cai M; Geng X; Zhang Y; Xia J; Zhang X; Li A; Liu S; Zhang W
Cell Rep Med; 2024 Feb; 5(2):101357. PubMed ID: 38237597
[TBL] [Abstract][Full Text] [Related]
12. PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment.
Parvez A; Choudhary F; Mudgal P; Khan R; Qureshi KA; Farooqi H; Aspatwar A
Front Immunol; 2023; 14():1296341. PubMed ID: 38106415
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules.
Yang J; Hu L
Med Res Rev; 2019 Jan; 39(1):265-301. PubMed ID: 30215856
[TBL] [Abstract][Full Text] [Related]
14. Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization.
Guo Y; Jin Y; Wang B; Liu B
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946261
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
Zak KM; Grudnik P; Guzik K; Zieba BJ; Musielak B; Dömling A; Dubin G; Holak TA
Oncotarget; 2016 May; 7(21):30323-35. PubMed ID: 27083005
[TBL] [Abstract][Full Text] [Related]
16. Discovery of quinazoline derivatives as novel small-molecule inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction.
Wang Y; Kun Huang ; Gao Y; Yuan D; Ling L; Liu J; Wu S; Chen R; Li H; Xiong Y; Liu H; Ma J
Eur J Med Chem; 2022 Feb; 229():113998. PubMed ID: 34839997
[TBL] [Abstract][Full Text] [Related]
17. Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy.
Yin S; Chen Z; Chen D; Yan D
Theranostics; 2023; 13(5):1520-1544. PubMed ID: 37056572
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
[TBL] [Abstract][Full Text] [Related]
19. From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway.
Zhan MM; Hu XQ; Liu XX; Ruan BF; Xu J; Liao C
Drug Discov Today; 2016 Jun; 21(6):1027-36. PubMed ID: 27094104
[TBL] [Abstract][Full Text] [Related]
20. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
